OraSure Technologies, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68554V1089
USD
2.57
0.07 (2.8%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About OraSure Technologies, Inc. stock-summary
stock-summary
OraSure Technologies, Inc.
Pharmaceuticals & Biotechnology
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.
Company Coordinates stock-summary
Company Details
150 WEBSTER ST , BETHLEHEM PA : 18015
stock-summary
Tel: 1 503 6416115
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 64 Schemes (42.13%)

Foreign Institutions

Held by 106 Foreign Institutions (10.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michael Celano
Independent Chairman of the Board
Dr. Stephen Tang
President, Chief Executive Officer, Director
Lelio Marmora
Director
Ms. Mara Aspinall
Independent Director
Mr. James Datin
Independent Director
Mr. Eamonn Hobbs
Independent Director
Mr. Ronny Lancaster
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
31 Million
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 238 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.61

stock-summary
Return on Equity

-12.77%

stock-summary
Price to Book

0.62